GlassScriptPhysician profile
Kimberly Cricchi
NPI 1174397558
$2,032.84
in general payments reported to CMS, 2019-2025
15 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $950 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $356.86 | 2024-2025 | Ibsrela |
| Abbvie INC. | $293.61 | 2024-2025 | |
| Qol Medical, LLC | $271.14 | 2024-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $203.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $157.95 | 2024-2025 | |
| Janssen Biotech, INC. | $155.05 | 2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $107.88 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $101.30 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $86.62 | 2024-2025 | |
| Celgene Corporation | $85.54 | 2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.08 | 2024-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $73.40 | 2024-2025 | Omvoh, Zepbound |
| Ferring Pharmaceuticals INC. | $25.95 | 2024 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $19.62 | 2025 | Eohilia |
| Fresenius Kabi USA, LLC | $18.97 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Cricchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.